首页> 外文OA文献 >PCN54 A COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS SECONDARY PROPHYLAXIS WITH COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS WITH DIFFUSE AGGRESSIVE LYMPHOMA RECEIVING CURATIVE-INTENT CHEMOTHERAPY USING ONTARIO HEALTH ECONOMIC DATA

【2h】

PCN54 A COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS SECONDARY PROPHYLAXIS WITH COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS WITH DIFFUSE AGGRESSIVE LYMPHOMA RECEIVING CURATIVE-INTENT CHEMOTHERAPY USING ONTARIO HEALTH ECONOMIC DATA

机译：PCN54对具有结肠刺激因素的老年人原发性前列腺炎与继发性前列腺炎的成本效度分析，采用本体健康经济数据，对接受恶性淋巴瘤的患者进行有创意的化疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Chan KKW; Krahn MD; Imrie K; Alibhai SM;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. [J] . Kelvin K W Chan, Eric Siu, Murray D Krahn, Journal of Clinical Oncology . 2012,第10期

机译：老年弥漫性侵袭性淋巴瘤患者接受根治性化疗的一级预防与二级预防与粒细胞集落刺激因子的成本-效用分析。
2. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: Cost-benefit and quality of life analysis [J] . LeeS., KnoxA., ZengI.S.L., Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer . 2013,第3期

机译：粒细胞集落刺激因子（GCSF）的一级预防可降低接受CHOP化疗的非霍奇金淋巴瘤（NHL）患者的发热性中性粒细胞减少症的发生，而不会对其生活质量产生不利影响：成本效益和生活质量分析
3. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis [J] . Chao Chun, Rodriguez Roberto, Page John H., Leukemia and lymphoma . 2015,第1期

机译：未接受粒细胞集落刺激因子预防的非霍奇金淋巴瘤患者的慢性合并症病史和化疗引起的发热性中性粒细胞减少症的风险
4. Effects of primary prophylaxis of neutropenia on outcomes, utilization and expenditures for elderly breast cancer patients receiving chemotherapy. [D] . Rajan, Suja S. 2009

机译：一级预防中性粒细胞减少对老年接受化疗的乳腺癌患者的结局，利用和支出的影响。
5. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy [O] . Xiao Jun Wang, Tiffany Tang, Mohamad Farid, -1

机译：对于非霍奇金淋巴瘤患者采用药性相似的粒细胞集落刺激因子（Nivestim）或培格非司汀常规预防发热性中性粒细胞减少是成本有效的接受治疗性R-CHOP化疗
6. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. [O] . Xiao Jun Wang, Tiffany Tang, Mohamad Farid, 2016

机译：生物类似物粒细胞集落刺激因子（Nivestim）或pegfilgrastim的常规原发性预防性发热性中性粒细胞减少症在接受治疗性意向R-CHOp化疗的非霍奇金淋巴瘤患者中具有成本效益。

PCN54 A COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS SECONDARY PROPHYLAXIS WITH COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS WITH DIFFUSE AGGRESSIVE LYMPHOMA RECEIVING CURATIVE-INTENT CHEMOTHERAPY USING ONTARIO HEALTH ECONOMIC DATA

著录项

引文网络

相似文献

相关主题

期刊订阅